MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

8 April 2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development of new health technologies for the developing world, through financing the United Nations Development Program (UNDP) and collaborating with the Global Health Innovative Technology Fund (GHIT), a non-profit organization based in Japan, that announced its establishment on April 8.

The GHIT was established between the government and a consortium of Japanese pharmaceutical companies (Astellas, Daiichi Sankyo, Eisai, Shionogi and Takeda) as well the Bill and Melinda Gates Foundation. It plans to attract further investment partners.

Currently, R&D efforts are insufficient for medicines of diseases that are disproportionally affecting developing countries, including neglected tropical diseases (NTDs), tuberculosis and malaria, due to small market incentives and a low demand for these medicines in developed countries. The international community is urged to provide people with access to affordable essential medicines, in cooperation with pharmaceutical companies.2

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK